Psoriatic Arthritis
From the Journals
MACE risk similar across arthritis subtypes
The older age of patients with rheumatoid arthritis explained most of their elevated risk of major adverse cardiovascular events.
Conference Coverage
How to avoid severe diarrhea from apremilast
Delayed up-titration of apremilast is often effective, albeit at cost of slower efficacy.
From the Journals
New PsA questionnaire fails to beat existing early screening methods
New eight-item CONTEST questionnaire matched the accuracy of the five-item PEST questionnaire.
Latest News
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
Anti-TNF alpha antibody biosimilar will enter European markets this year, but won’t be in United States until 2023.
Daily News Podcast
MDedge Daily News: Does more marijuana mean fewer opioids?
And acutely ill patients may not get enough venous thromboembolism prophylaxis.
From the Journals
Most PsA patients discontinue initial biologic within 12 months
The results “suggest a high frequency of suboptimal biologic experience in patients with PsA.”
From the Journals
Study using U.K. data quantifies infection risk associated with psoriasis
The most common serious infections were lower respiratory tract, skin and soft tissue, and upper respiratory tract infections.
News
FDA approves certolizumab label update for pregnancy, breastfeeding
Approval is based on data from the CRIB and CRADLE studies.
Latest News
FDA approves IL-23 antagonist for plaque psoriasis
Approval is based on data from two phase 3, identically designed clinical trials, reSURFACE1 and reSURFACE2.
From the Journals
Ultrasound study supports deep Koebner mechanism in PsA pathology
Digital accessory pulleys are thicker in PsA patients than in those with RA or psoriasis only.
Conference Coverage
PASI responses with biologics similar among white, nonwhite individuals, study finds
MIAMI– Investigators used data from psoriasis studies to determine whether treatment responses differed in skin of color patients.